A. Wagman

发表

Chapter 19. Recent advances in therapeutic approaches to type 2 diabetes

J. Nuss, A. Wagman, 2000 .

Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor

J. Ruzzin, A. Wagman, J. Jensen, 2005, Diabetologia.

Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitors.

Sean P. Brown, E. Fang, M. Desai, 2019, Bioorganic & medicinal chemistry letters.

4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors.

Z. Ni, D. Bussiere, S. Ramurthy, 2006, Bioorganic & medicinal chemistry letters.

Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.

Sean P. Brown, Kirk W. Johnson, Z. Ni, 2017, Journal of medicinal chemistry.

Current therapies and emerging targets for the treatment of diabetes.

J. Nuss, A. Wagman, 2001, Current pharmaceutical design.

Current Therapies and Emerging Targets for the Treatment of Diabetes

J. Nuss, A. Wagman, 2004 .

Ring-closing olefin metathesis for the synthesis of fused nitrogen heterocycles

Hui-ju Chen, S. Martin, A. Wagman, 1996 .

Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1.

D. Green, E. Dejardin, C. Charvet, 2006, Molecular cell.

Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitors.

Sean P. Brown, E. Fang, M. Desai, 2019, Bioorganic & medicinal chemistry letters.

Progress and development of small molecule HCV antivirals.

Z. Ni, A. Wagman, 2004, Current opinion in drug discovery & development.

A general method for the synthesis of 1,1-difluoroalkylphosphonates

S. Martin, A. Wagman, D. Dean, 1992 .

Total Synthesis of (.+‐.)‐Ginkgolide B.

James B. Thomas, P. Nantermet, M. Crimmins, 2010 .

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.

Simon Ng, Yanchen Zhang, Kenneth Crawford, 2011, ACS medicinal chemistry letters.

Chapter 19. Antibacterial treatment of community-acquired respiratory tract INFECTIONS

A. Wagman, Mary Lee, 2003 .

A NOVEL APPROACH TO FR-900482 VIA RING FORMING METATHESIS

S. Martin, A. Wagman, 1995 .

Synthesis and Microbiological Evaluation of Novel Tetracyclic Fluoroquinolones

T. Poel, H. Moser, A. Wagman, 2017, ChemMedChem.

Synthesis and Kinetic Evaluation of Inhibitors of the Phosphatidylinositol-Specific Phospholipase C from Bacillus cereus.

S. Martin, A. Wagman, 1996, Journal of Organic Chemistry.

Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target.

G. Duke, W. McCulloch, T. Heuer, 2017, Pharmacology & therapeutics.

Synthesis and Kinetic Evaluation of Inhibitors of the Phosphatidylinositol‐Specific Phospholipase C from Bacillus cereus.

S. Martin, A. Wagman, 1997 .

A general and efficient route to phosphorodithioate analogs of naturally occurring lipids

S. Martin, A. Wagman, 1993 .

Design, Synthesis, and Evaluation of Phospholipid Analogs as Inhibitors of the Bacterial Phospholipase C from Bacillus cereus

S. Martin, A. Wagman, Y. Wong, 1994 .

Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.

Kirk W. Johnson, Sylvia Ma, J. Nuss, 2003, Diabetes.

Exploring the active site of the Streptococcus pneumoniae topoisomerase IV–DNA cleavage complex with novel 7,8-bridged fluoroquinolones

I. Laponogov, L. Fisher, H. Moser, 2016, Open Biology.

7.19 – Quinolone Antibacterial Agents

A. Wagman, 2007 .

A long-wavelength biolabeling reagent based on the oxonol fluorophore

A. Waggoner, J. Chao, A. Wagman, 1995, Journal of Fluorescence.

Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.

Kirk W. Johnson, D. Bussiere, A. Wagman, 2004, Current pharmaceutical design.

Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors.

E. Iwanowicz, Z. Ni, T. Hendrickson, 2011, ACS medicinal chemistry letters.

Abstract 4446: Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis

Richard Ventura, J. Waszczuk, T. Heuer, 2015 .